Brought to you by 
SAGE Therapeutics closes $38mm Series C round to support SAGE547 Phase I/II trial
28 Mar 2014
Executive Summary
Only five months after closing its $20mm Series B round, orphan CNS drug developer SAGE Therapeutics Inc. raised $38mm in an oversubscribed Series C financing. Returning shareholders Third Rock Ventures and Arch Venture Partners were joined by first-time investors OrbiMed Advisors, EcoR1 Capital Management, Foresite Capital Management, and two undisclosed blue chip public investment funds. The start-up will apply the new funding to lead candidate SAGE547, a GABA A positive allosteric modulator. Patients with super refractory status epilepticus are currently enrolling in a Phase I/II trial.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SAGE Therapeutics closes $38mm Series C round to support SAGE547 Phase I/II trial
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice